A 16 week open-label outpatient, randomized, parallel study assessing the impact of two different initial dose prescriptions for dry powder inhaled insulin (Exubera) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on a combination of two or more oral agents.

Trial Profile

A 16 week open-label outpatient, randomized, parallel study assessing the impact of two different initial dose prescriptions for dry powder inhaled insulin (Exubera) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on a combination of two or more oral agents.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 May 2008

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 May 2008 Status changed from recruiting to discontinued (because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007).
    • 18 Oct 2007 Trial centre added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top